by mpzzqmvj | Jan 9, 2023 | Press Releases
– Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying...
by mpzzqmvj | Jan 4, 2023 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Jan 4, 2023 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Dec 30, 2022 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Nov 11, 2022 | Press Releases
– Quarter marked by launch of Phase 2b study of Trappsol® Cyclo™ for the treatment of early Alzheimer’s Disease (AD) with patient enrollment and site activation now underway – Building momentum with ongoing advancement of global pivotal...
